s Comtan. Mylan Inc. said Thursday that it had reached an agreement to settle patent litigation over the generic version of Orion Corp.'s Comtan. Financial terms of the agreement, which will ...

5,446,194 covering Comtan ® against Mylan Pharmaceuticals Inc. (Mylan). Mylan seeks authorisation to produce and market a generic version of entacapone 200 mg tablets in the United States.

Sun Pharmaceutical on Tuesday said it has settled patent litigation with Finland-based Orion over generic versions of Stalevo and Comtan tablets, which are used for the treatment of Parkinson's ...

Entacapone tablet is the generic name for the brand Comtan®, owned by Orion Corporation and marketed in the US by Novartis. Wockhardt will launch the product on September 30, 2012, according to ...

Comtan has no anti-Parkinson’s activity of its own, but it improves the efficacy of carbidopa/levodopa. The first indication of risk for Stalevo, the agency said, came from a clinical trial ...

Entacapone is the active ingredient in Comtan®, a product originated by Orion Corporation for Parkinson's disease and marketed in the United States by its exclusive licensee, Novartis.

Ltd. ("Lotus") have made a marketing and distribution agreement for Orion's Parkinson's disease drugs Stalevo and Comtan in parts of Asia. According to the agreement, Lotus will, starting Q3 2020 ...

In addition to these, Sun Pharma will be able to launch generic versions of other dosages of Stalevo on 2 October 2012 and generic versions of Comtan on 1 April 2013, unless certain conditions ...

Drug firm Wockhardt on Monday said it will launch a generic version of Finnish company Orion Corporation's Comtan tablets, used in treating Parkinson's disease, in the US with 180 days of ...

The company is also to sell Orion’s Comtan, another drug used to treat Parkinson’s disease, in Taiwan, Hong Kong, the Philippines and South Korea, it added. Novartis Pharma AG currently holds the ...

Entacapone is also available as a single-ingredient product sold under the brand name Comtan. Both Stalevo and Comtan are used to treat symptoms of Parkinson's disease. The data being reviewed are ...